# Hepatitis C: State of Medicaid Access Report Card

# **New Hampshire**



Grade	Recommendations to Improve Patient Access		
A	Ensure transparency and parity across FFS and MCOs regarding HCV coverage criteria.		

#### **State Overview**

As of October 2022, 244,752 individuals were enrolled in Medicaid and CHIP in New Hampshire.<sup>1</sup> It is estimated that as of 2016, 7,700 people were living with HCV in New Hampshire.<sup>2</sup> New Hampshire Medicaid operates a fee-for-service (FFS) program and contracts with managed care organizations (MCOs).<sup>3</sup> Most beneficiaries, 98 percent, are enrolled in an MCO, and the remaining 2 percent participate in FFS.<sup>4</sup> New Hampshire Medicaid contracts with three managed care organizations (MCOs): AmeriHealth Caritas New Hampshire (AmeriHealth), NH Healthy Families, and Well Sense Health Plan (Well Sense).<sup>5</sup>

The New Hampshire Medicaid Preferred Drug List lists ledipasvir/sofosbuvir, Mavyret, sofosbuvir/velpatasvir, and Vosevi as preferred regimens.<sup>6</sup>

Deductions		Policy		
Prior Authorization		For treatment-naïve individuals (1-year lookback), prior authorization is not required if they are prescribed a preferred regimen. <sup>7</sup>		
Fibrosis Restrictions		New Hampshire Medicaid does not impose fibrosis restrictions. <sup>8</sup>		
Substance Use Restrictions		New Hampshire Medicaid does not impose substance use restrictions. <sup>9</sup>		
Prescriber Restrictions		New Hampshire Medicaid does not impose prescriber restrictions. 10		
Retreatment Restrictions		New Hampshire Medicaid does not impose undue retreatment restrictions. 11 For patients that are treatment experienced, the state requires that the prescription must be prescribed by or in consultation with a specialist, "or the prescriber must have completed continuing medical education on the treatment of hepatitis C." 12		
Access in Managed Care	-8	All MCOs, AmeriHealth <sup>13</sup> , NH Healthy Families <sup>14</sup> , and Well Sense <sup>15</sup> appear to require prior authorization. Additionally, AmeriHealth Caritas requires that the "provider attests if member is actively abusing alcohol or IV drugs or has a history of abuse that they have counseled member regarding the risks of alcohol or IV drug abuse, and an offer of referral for substance abuse disorder treatment has been made." 16 NH Healthy Families does not publish hepatitis C coverage criteria. 17		
Additional Restrictions		New Hampshire Medicaid does not impose any additional restrictions. <sup>18</sup>		
Total Deductions		Total Score [100-Deductions]	Grade	
-8		92	Α	

## **Contact Your State Officials**

Medicaid Office<sup>19</sup>: Henry Lipman, Medicaid Director, Office of Medicaid Business & Policy, New Hampshire Department of Health & Human Services

129 Pleasant Street, Concord, NH 03301; Telephone: (603) 271-4344

**Drug Utilization Review Board<sup>20</sup>: Margaret "Peg" Clifford, NH Department of Health and Human Services** 129 Pleasant Street, Concord, NH, 03301; Telephone: (603) 271-9422; Email Address: Margaret.clifford@dhhs.nh.gov





### **Key Sources**

Preferred Drug List: New Hampshire Medicaid Preferred Drug List (Jan. 31, 2023) Clinical Criteria: New Hampshire Medicaid, Hepatitis C Criteria (Jan. 14, 2022)



 $<sup>^1\,</sup> Centers \, for \, Medicaie \, \& \, Medicaid \, \& \, CHIP \, in \, New \, Hampshire: \, https://www.medicaid.gov/medicaid/by-state/stateprofile.html?state=new-hampshire.$ 

<sup>&</sup>lt;sup>2</sup> HepVu, Local Data: New Hampshire: https://hepvu.org/state/new-hampshire.

<sup>&</sup>lt;sup>3</sup> New Hampshire Department of Health & Human Services, Medicaid Care Management, https://perma.cc/9CZ9-4MFM.

<sup>&</sup>lt;sup>4</sup> Kaiser Family Foundation, Share of Medicaid Population Covered Under Different Delivery Systems (July 1, 2022), https://perma.cc/EMN8-QR8B.

<sup>&</sup>lt;sup>5</sup> New Hampshire Department of Health & Human Services, Medicaid Care Management, https://perma.cc/9CZ9-4MFM.

<sup>&</sup>lt;sup>6</sup> Preferred Drug List.

<sup>&</sup>lt;sup>7</sup> Clinical Criteria.

<sup>&</sup>lt;sup>8</sup> Clinical Criteria.

<sup>&</sup>lt;sup>9</sup> Clinical Criteria.

<sup>&</sup>lt;sup>10</sup> Clinical Criteria.

<sup>&</sup>lt;sup>11</sup> Clinical Criteria.

<sup>&</sup>lt;sup>12</sup> Clinical Criteria

<sup>&</sup>lt;sup>13</sup> AmeriHealth Caritas New Hampshire, Prior Authorization Criteria (December 27, 2022), https://perma.cc/54EN-SCR6.

<sup>&</sup>lt;sup>14</sup> NH Healthy Families, Preferred Drug List (Feb. 1, 2023), https://perma.cc/FWY7-XKL9.

<sup>&</sup>lt;sup>15</sup> Well Sense, Pharmacy Policy: Hepatitis C (Sept. 1, 2022), https://perma.cc/DV5X-4TUB.

<sup>&</sup>lt;sup>16</sup> AmeriHealth Caritas New Hampshire Prior Authorization Criteria (December 27, 2022), https://perma.cc/54EN-SCR6.

<sup>&</sup>lt;sup>17</sup>NH Health Families, Pharmacy: https://perma.cc/75B5-ACRP.

<sup>&</sup>lt;sup>18</sup> Clinical Criteria.

<sup>&</sup>lt;sup>19</sup> National Association of Medicaid Directors, Medicaid Directors (accessed Jan. 2023), https://perma.cc/TG6Y-BQFA.

<sup>&</sup>lt;sup>20</sup>New Hampshire Department of Health & Human Services, Drug Utilization Review Board, Public Hearing (December 13, 2022): https://perma.cc/H2XE-LH93.